Song, Ling
Cao, Fangrui
Niu, Shu
Xu, Michael
Liang, Ruifang
Ding, Ke
Lin, Zhigang
Yao, Xueting
Liu, Dongyang http://orcid.org/0000-0001-6446-0127
Funding for this research was provided by:
National Natural Science Foundation of China (82373954, 8217389)
Bill and Melinda Gates Foundation (INV-007625)
Peking University Third Hospital Clinical Project (BYSYFY2021006)
Article History
Accepted: 11 October 2023
First Online: 20 November 2023
Declarations
:
: The study was supported by the National Natural Science Foundation of China (no. 82173895 and no. 82373954), The Bill & Melinda Gates Foundation (Grant/Award Number: INV-007625) and the Peking University Third Hospital Clinical Project (Grant/Award Number: BYSYFY2021006).
: Michael Xu, Ruifang Liang, Ke Ding, and Zhigang Lin are employees of PegBio Co., Ltd., (Suzhou, Jiangsu, China) the company that owns PB201. Ling Song, Fangrui Cao, and Dongyang Liu have no conflicts of interest that are directly relevant to the content of this article.
: The data used in this study were collected in line with the principles of the Declaration of Helsinki. Approval was granted by institutional review boards and independent ethics committees for each study of which data were used in this work.
: Not applicable.
: Not applicable.
: All data generated or analyzed during this study are included in this published article (and its supplementary information files).
: Not applicable.
: LS, FC, and DL designed the study. LS and FC conducted the modeling and simulation work. MX, RL, KD, and ZL provided the clinical raw data.